全球幽门螺旋桿菌（H. pylori）非侵入性检测市场规模（按检测类型、最终用户、地区、范围和预测）

非侵入性幽门螺旋桿菌（H. pylori）检测市场规模的变化及预测

2024 年幽门螺旋桿菌 (H. pylori) 非侵入性检测市场规模价值 6.903 亿美元，预计到 2032 年将达到 9.3082 亿美元，2026 年至 2032 年的复合年增长率为 4.20%。

非侵入性幽门螺旋桿菌 (H. pylori) 检测包括尿素呼气试验、粪便抗原检测和血清学检测，这些检测无需内视镜检查即可诊断病菌感染。尿素呼吸检测需要摄取一种碳同位素标记的尿素溶液（此尿素溶液可被幽门螺旋桿菌代谢），并检测呼气中的二氧化碳。粪便抗原检测可检测粪便中的 H. pylori 蛋白，而血清学检测可检测血液中的 H. pylori 抗体。

这些检测对于确定幽门螺旋桿菌病菌感染至关重要，幽门螺旋桿菌感染是消化性溃疡和胃癌的主要原因。这些检测提供了一种便捷、患者友善的治疗方法，可以取代内视镜切片检查等侵入性治疗。非侵入性检测对于早期诊断、治疗后监测以及筛检幽门螺旋桿菌相关疾病风险族群至关重要。

非侵入性检测的进步旨在提高准确性、降低成本并增加可及性。分子诊断和即时诊断等新技术将彻底改变幽门螺旋桿菌的检测方式，从而实现广泛的筛检和早期疗育。个人化医疗方法也可能包括非侵入性诊断，以调整治疗策略，从而减轻全球幽门螺旋桿菌相关疾病的负担。

幽门螺旋桿菌（H. pylori）非侵入性检测的全球市场动态

关键市场驱动因素

病菌感染不断上升：全球病菌感染不断上升，尤其是在开发中国家，这推动了对非侵入性检测的需求。人们认识到与幽门螺旋桿菌相关的健康危害，例如消化性溃疡和胃癌，这凸显了快速便捷的诊断工具的重要性。

非侵入性诊断的偏好：尿素呼气试验、粪便抗原检测和血清学检测等非侵入性检测相比侵入性治疗具有许多优势，包括提高患者舒适度、降低併发症风险以及易于操作。这些偏好推动了非侵入性诊断在临床实务中的应用。

技术进步与创新：诊断技术的不断开拓，包括开发更准确、更具成本效益和更快速的检测方法，正在推动市场扩张。分子诊断和即时检测的技术创新正在提高幽门螺旋桿菌诊断的效率和可及性，从而推动市场成长。

主要挑战

准确性和可靠性担忧：幽门螺旋桿菌的非侵入性诊断方法虽然便捷，但有时会出现假阳性或假阴性结果。尤其是血清学检测，其准确性参差不齐，可能发现既往疾病而非当前疾病，这使得可靠的诊断和监测变得困难。

成本和可近性问题：儘管技术不断发展，但某些非侵入性诊断方法（例如尿素呼气试验）的成本可能过高，难以广泛应用，尤其是在低收入人群中。农村和服务欠缺地区难以获得先进的实验室和设备，阻碍了这些诊断方法的广泛应用。

抗生素抗药性：抗生素抗药性的增加影响了病菌感染的治疗。除了非侵入性检测外，还必须进行抗生素敏感性测试以确保适当的治疗，但这种测试很复杂，并且会增加诊断的成本和时间。

主要趋势：

采用就地检验(POC)：市场正转向照护现场诊断设备，这些设备可在患者所在位置提供快速且准确的结果。此类照护现场设备在初级基层医疗机构和偏远地区尤其有用，因为它们提高了可近性，最大限度地减少了等待时间，并提高了患者的依从性。

先进分子诊断技术的整合：非侵入性幽门螺旋桿菌检测越来越多地采用分子诊断技术，例如聚合酵素链锁反应(PCR) 和次世代定序(NGS)。这些方法提高了灵敏度和特异性，从而能够更准确地检测和鑑定感染情况。

个人化医疗和标靶治疗：个人化医疗的日益增长趋势正在影响幽门螺旋桿菌检测市场。目前正在开发的非侵入性检测方法，可以检测细菌的存在，并同时提供有关抗生素抗药性模式的资讯。这些资讯有助于制定针对每位患者病情的个人化治疗策略，从而改善治疗效果并降低抗生素抗药性的风险。

目录

第一章 引言

• 市场定义
• 市场区隔
• 调查方法

第二章执行摘要

• 主要发现
• 市场概览
• 市集亮点

第三章市场概述

• 市场规模和成长潜力
• 市场趋势
• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析

4. 幽门螺旋桿菌（H. pylori）非侵入性检测市场（依检测类型划分）（诊断）

• 尿素呼气试验（UBT）
• 粪便抗原检测（HpSA）
• 血清学检测

5. 幽门螺旋桿菌（H. pylori）非侵入性检测市场（依最终使用者）

• 医院
• 诊断实验室
• 诊所

第六章区域分析

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利
• 亚太地区
• 中国
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中东和非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯聯合大公国

第七章市场动态

• 市场驱动因素
• 市场限制
• 市场机会
• COVID-19 市场影响

第八章 竞争态势

• 主要企业
• 市场占有率分析

第九章 公司简介

• Abbott
• Biomerica, Inc.
• Certest Biotec SL
• CorisBioconcept SPRL
• DiaSorin SpA
• Exalenz Bioscience Ltd.
• Meridian Bioscience, Inc.
• Sekisui Diagnostics
• Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd.

第十章 市场展望与机会

• 新兴技术
• 未来市场趋势
• 投资机会

第十一章 市场展望 附录

• 简称列表
• 来源和参考文献

Helicobacter Pylori (H. Pylori) Non-Invasive Testing Market Size And Forecast

Helicobacter Pylori (H. Pylori) Non-Invasive Testing Market size was valued at USD 690.3 Million in 2024 and is projected to reach USD 930.82 Million by 2032, growing at a CAGR of 4.20% from 2026 to 2032.

Helicobacter pylori (H. pylori) non-invasive testing includes urea breath tests, stool antigen tests and serology tests that diagnose H. pylori infection without the need for an endoscopy. The urea breath test involves consuming a urea solution labeled with a carbon isotope which H. pylori metabolizes resulting in detectable carbon dioxide in the breath. Stool antigen tests detect H. pylori proteins in feces whereas serology tests detect antibodies to H. pylori in the bloodstream.

These tests are critical in determining H. pylori infection which is a leading cause of peptic ulcers and stomach cancer. They provide a convenient and patient-friendly alternative to invasive treatments such as endoscopic biopsies. Non-invasive testing is critical for initial diagnosis, post-treatment monitoring and screening in populations at risk of H. pylori-related illnesses.

Non-invasive testing advancements are intended to improve accuracy, lower costs and increase accessibility. Emerging technologies such as molecular techniques and point-of-care diagnostics are set to transform H. pylori detection allowing for broad screening and early intervention. Personalized medicine approaches may also include non-invasive diagnostics to adapt treatment strategies lowering the worldwide burden of H. pylori-related disorders.

Global Helicobacter Pylori (H. Pylori) Non-invasive Testing Market Dynamics

The key market dynamics that are shaping the global helicobacter pylori (h. pylori) non-invasive testing market include:

Key Market Drivers:

Increased Prevalence of H. Pylori Infections: The rising global incidence of H. pylori infections particularly in developing nations is driving the demand for non-invasive testing. Recognizing the health hazards associated with H. pylori such as peptic ulcers and stomach cancer emphasizes the importance of quick and accessible diagnostic tools.

Preference for Non-Invasive Diagnostic Methods: Non-invasive examinations such as urea breath tests, stool antigen testing and serology tests provide several advantages over invasive treatments including increased patient comfort, a lower risk of complications and ease of administration. This preference promotes the use of non-invasive diagnostics in clinical settings.

Technological Advancements and Innovation: Constant developments in diagnostic technology such as the creation of more accurate, cost-effective and rapid testing methods drive market expansion. Innovations in molecular diagnostics and point-of-care testing improve the efficiency and accessibility of H. pylori diagnosis propelling market growth.

Key Challenges:

Accuracy and Reliability Concerns: Non-invasive diagnostics for H. pylori while handy, can occasionally provide false positives or negatives. Variations in test accuracy particularly with serology tests that may reveal past rather than current illnesses make it difficult to provide reliable diagnosis and surveillance.

Cost and Accessibility Issues: Despite technical developments, the cost of certain non-invasive diagnostics such as the urea breath test can be too expensive for broad use especially in low-income communities. Limited access to advanced testing facilities and equipment in rural and underserved areas impedes widespread use of these diagnostic approaches.

Antibiotic Resistance: The increasing prevalence of antibiotic resistance affects the treatment of H. pylori infections. Non-invasive tests must be supplemented by antibiotic susceptibility testing to ensure appropriate therapy which adds complexity and may increase the cost and duration of the diagnostic procedure.

Key Trends:

Adoption of Point-of-Care Testing: The market is shifting toward point-of-care (POC) diagnostic instruments that deliver quick and precise results at the patient's location. These point-of-care diagnostics improve accessibility, minimize wait times and increase patient compliance making them especially useful in primary care settings and remote places.

Integration of Advanced Molecular Diagnostics: In non-invasive H. pylori testing, molecular diagnostic technologies such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) are increasingly being used. These approaches have improved sensitivity and specificity allowing for more precise detection and characterization of infections.

Personalized Medicine and Targeted Therapy: The expanding trend of personalized medicine is influencing the H. pylori testing market. Non-invasive assays are being developed to detect the presence of bacteria while simultaneously providing information about antibiotic resistance patterns. This information allows treatment strategies to be tailored to each individual patient's illness profile increasing treatment outcomes and lowering the risk of antibiotic resistance.

Global Helicobacter Pylori (H. Pylori) Non-invasive Testing Market Regional Analysis

Here is a more detailed regional analysis of the global Helicobacter pylori (H. pylori) non-invasive testing market:

North America:

According to Verified Market Research analyst, North America is expected to dominate the global Helicobacter pylori (H. pylori) non-invasive testing market.

The region's dominance is due to a number of major factors. The region's high healthcare expenditure ensures access to new diagnostic technologies and allows for the rapid adoption of innovative, non-invasive testing methods. Furthermore, favorable payment rules significantly reduce patient's out-of-pocket expenses making these tests more affordable and encouraging widespread adoption. The combination of robust healthcare infrastructure and strong financial incentives fosters market expansion.

Furthermore, North America has a large patient population with H. pylori infections which fuels demand for diagnostic testing. Awareness campaigns and public health initiatives also play an important role in promoting early detection and regular screening which helps grow the market. The region's emphasis on preventative healthcare combined with the high frequency of gastrointestinal illnesses associated with H. pylori highlights the vital need for dependable diagnostic solutions solidifying North America's dominance in the H. pylori non-invasive market.

Asia Pacific:

The Asia Pacific region is expected to become the fastest-growing market for H. pylori non-invasive testing market driven by rising infection rates. H. pylori infection rates are high in countries such as China, India and Japan necessitating appropriate diagnostic techniques to control and treat gastrointestinal problems. The increased incidence of H. pylori infections underscores the critical need for accessible and reliable diagnostic technologies which is driving market expansion in the region.

Growing healthcare infrastructure in Asia Pacific contributes greatly to this expansion. Investments in updating healthcare facilities and increasing access to innovative medical technologies are helping the region's diagnostic capacities. Governments and corporate entities are prioritizing healthcare advancements resulting in better-equipped hospitals and clinics which encourages the use of non-invasive H. pylori testing procedures.

The region's enormous population base creates a significant market opportunity for H. pylori non-invasive diagnostics. With Asia Pacific home to a sizable fraction of the world's population, there is an enormous potential need for diagnostic services. Furthermore, rising awareness of H. pylori-related health conditions as well as a growing middle class with better access to healthcare facilities are driving up demand for improved therapies. These factors combine to position the Asia Pacific region as a prominent player in the future growth of the H. pylori non-invasive testing market.

Global Helicobacter Pylori (H. Pylori) Non-invasive Testing Market: Segmentation Analysis

The Global Helicobacter Pylori (H. Pylori) Non-invasive Testing Market is segmented on the basis of Test Type, End User, and Geography.

Helicobacter Pylori (H. Pylori) Non-invasive Testing Market, By Test Type

• Urea Breath Test (UBT)
• Stool Antigen Test (HpSA)
• Serological Testing

Based on Test Type, the market is Urea Breath Test (UBT), Stool Antigen Test (HpSA) and Serological Testing. The Urea Breath Test (UBT) dominates the H. pylori non-invasive testing market due to its high accuracy, non-invasiveness and rapid findings. UBT is preferred because it can detect active infections more accurately and is less impacted by recent antibiotic or proton pump inhibitor usage than other tests. It is the most reliable and patient-friendly method for diagnosing H. pylori infections.

Helicobacter Pylori (H. Pylori) Non-invasive Testing Market, By End User

• Hospitals
• Diagnostic Labs
• Clinics

Based on End User, the market is divided into Hospitals, Diagnostic Labs and Clinics. Hospitals dominate the market for H. pylori non-invasive testing because of their modern diagnostic centers, extensive patient care and high patient volume. Hospitals are frequently the primary facilities for diagnosing and treating gastrointestinal illnesses including H. pylori infections. Their comprehensive diagnostic test suite along with integrated care and follow-up therapies guarantees that they will always be the go-to option for precise and effective H. pylori testing.

Helicobacter Pylori (H. Pylori) Non-invasive Testing Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World
• On the basis of Geography, the Global Helicobacter Pylori (H. Pylori) Non-invasive Testing Market is classified into North America, Europe, Asia Pacific and the Rest of the world. North America dominates the H. pylori non-invasive testing market owing to high healthcare spending, attractive reimbursement rules and a large patient population. In contrast, the Asia Pacific region is rapidly emerging as the fastest-growing market driven by rising infection rates, improved healthcare infrastructure and a large population base that requires advanced diagnostic solutions.

Key Players

• The Global Helicobacter Pylori (H. Pylori) Non-invasive Testing Market study report will provide valuable insight with an emphasis on the global market. The major players in the market are Abbott, Biomerica Inc., Certest Biotec S.L., CorisBioconcept SPRL, DiaSorin S.p.A., Meridian Bioscience Inc., Sekisui Diagnostics and Shenzhen Zhonghe Headway Bio-Sci & Tech Co. Ltd.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

• Helicobacter Pylori (H. Pylori) Non-invasive Testing Market Recent Developments
• In March 2023, RedHill, a speciality biopharmaceutical company declared that it has settled all of its debt, including principal, interest, revenue interest, prepayment premiums and exit costs. This contains RedHill Biopharma Inc.'s (the company's U.S. subsidiary) Credit Agreement with HCR.
• In July 2023, Meridian Bioscience received FDA clearance for Premier HpSA Flex, a significant advancement in non-invasive H. pylori diagnostic testing solutions. This milestone strengthened the company's position in the non-invasive H. pylori testing market.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Helicobacter Pylori (H. Pylori) Non-Invasive Testing Market, By Test Type (Diagnostics)

• Urea Breath Test (UBT)
• Stool Antigen Test (HpSA)
• Serological Testing

5. Helicobacter Pylori (H. Pylori) Non-Invasive Testing Market, By End User

• Hospitals
• Diagnostic Labs
• Clinics

6. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

7. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

8. Competitive Landscape

• Key Players
• Market Share Analysis

9. Company Profiles

• Abbott
• Biomerica, Inc.
• Certest Biotec S.L.
• CorisBioconcept SPRL
• DiaSorin S.p.A.
• Exalenz Bioscience Ltd.
• Meridian Bioscience, Inc.
• Sekisui Diagnostics
• Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd.

10. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

11. Appendix

• List of Abbreviations
• Sources and References